Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 403

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 403
---
2024. 9. Net Loss per Share The following table sets forth the computation of basic and diluted net loss per share of common stock for the six months ended June 30, 2025 and 2024 (in thousands, except share and per share data):

|                                                                                       |     | Six Months Ended 
 June 30,         |    2025 |   |     |   |    2024 |   |
|:--------------------------------------------------------------------------------------|:----|:-----------------|--------:|:--|:----|:--|--------:|:--|
| Net loss                                                                              |     | $                | (10,177 | ) |     | $ | (43,850 | ) |
| Weighted average shares outstanding used in calculating net loss per share, basic and 
 diluted (1)                                                                           |     |                  | 359,438 |   |     |   | 357,475 |   |
| Net loss per share, basic and diluted                                                 |     | $                |  (28.31 | ) |     | $ | (122.67 | ) |

| (1) | Included within weighted average shares of common stock outstanding for the six months ended June 30, 2025                                                                                                                                       
 and 2024 are 114,004 and 114,187 shares of common stock issuable upon the exercise of penny warrants, respectively. Per ASC 260, Earnings Per Share, the warrants are exercisable at any time for nominal consideration, and as such, the shares 
 are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.                                                                                                              |

The Company’s potentially dilutive securities, which consist primarily of stock options and convertible preferred stock, have been excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive impact. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potentially dilutive shares, presented based on amounts outstanding at each period end, have been excluded from the calculation of diluted net loss per share (in thousands):

|                                        |     |     | June 30, 
     2025 |     |     | June 30, 
     2024 |
|:---------------------------------------|:----|:----|---------:|:----|:----|---------:|
| Redeemable convertible preferred stock |     |